For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Bone Health & Osteoporosis: What the Human Evidence Shows

Content updated · how dates work

Bone remodeling, osteoporosis, and calcium regulation.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Bone & calcium: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for bone & calcium: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
FDA-approved medicine (4)Approved for the specific uses on its label, which may not be this goal.
AbaloparatideACTIVE (2016) · Human randomized trial
New vertebral and nonvertebral fractures were less frequent with abaloparatide than placebo, and bone mineral density increased. Hypercalcemia occurred in 3.4% with abaloparatide versus 6.4% with teriparatide.
Limitation: The trial addresses fracture prevention in osteoporosis. The open-label comparator and selected population limit claims of universal superiority or benefit for healthy athletes.
Studied: 2,463 postmenopausal women with osteoporosis.
FDA-approvedFDA label
Calcitonin salmonPROOF (2000) · Human randomized trial
The prespecified middle-dose group had fewer new vertebral fractures than placebo: 51/287 versus 70/270; relative risk 0.67. The other dose groups did not significantly differ from placebo.
Limitation: Only 511 participants completed five years. Attrition and the inconsistent dose response matter. Nasal-spray findings should not be transferred automatically to injectable products or every fracture type.
Studied: 1,255 postmenopausal women with established osteoporosis.
FDA-approvedFDA label
TeriparatideFracture Prevention Trial (2001) · Human randomized trial
New vertebral fractures occurred in 14% with placebo versus 5% and 4% in the active groups. Bone mineral density also increased.
Limitation: This is fracture-prevention evidence in osteoporosis. It does not establish accelerated healing of every sports injury or benefit in people with normal bone density.
Studied: 1,637 postmenopausal women with prior vertebral fractures.
FDA-approvedFDA label
VosoritideVosoritide in children with achondroplasia (2020) · Human randomized phase 3 trial
Adjusted annualized growth velocity was 1.57 cm/year higher with vosoritide, with a 95% CI of 1.22–1.93 cm/year.
Limitation: This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates.
Studied: 121 children aged five to under 18 years with achondroplasia.
FDA-approvedFDA label
Randomized human trials (1)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
TP-508TP-508 (Chrysalin) applied to diabetic foot ulcers (2007) · Human randomized phase 1/2 trial
Among participants treated as planned (per protocol), complete healing was more than twice as common with TP-508 as with placebo, the average closure rate was about 80% higher, and median time to full closure was about 40% shorter. Heel ulcers showed the largest difference: 6 of 7 healed completely with TP-508 versus 0 of 5 with placebo. Wound reactions and adverse events were similar between groups.
Limitation: A small pilot trial whose reported benefits come from the per-protocol group, not necessarily everyone randomized, and the heel-ulcer result rests on 12 ulcers. No larger diabetic foot ulcer trial was found, and the later phase 3 fracture trial missed its main clinical goal.
Studied: 60 adults with diabetic foot ulcers receiving standardized wound care and off-loading.
Not approvedTrials only

Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.

Abaloparatide

Abaloparatide is a bone-forming prescription medicine for osteoporosis. Its clinically relevant outcome is prevention of fractures in appropriately selected patients.

Prescription medicines

Read the studies →

Calcitonin salmon

Salmon calcitonin is a hormone medicine that reduces bone breakdown. Injectable and nasal preparations have distinct clinical histories and instructions.

Prescription medicines

Read the studies →

Teriparatide

Teriparatide is a parathyroid-hormone-related medicine used in osteoporosis care. Fracture reduction is a more direct clinical outcome than a bone marker alone.

Prescription medicines

Read the studies →

TP-508

TP-508, also called rusalatide acetate or Chrysalin, is a lab-made 23-amino-acid peptide copied from part of thrombin, a protein involved in blood clotting and tissue repair. It was tested in people for diabetic foot ulcers and wrist fractures. A large phase 3 fracture trial missed its main goal, no later human trials are registered, and it is not approved.

Research topics

Read the studies →

Vosoritide

Vosoritide is a C-type natriuretic peptide analogue studied for growth in children with achondroplasia. Its disease-specific evidence does not support height-increase claims for healthy adults.

Prescription medicines

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →